SGMO Sangamo Therapeutics Inc

Price (delayed)

$8.01

Market cap

$1.17B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.27

Enterprise value

$1.02B

Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients' lives using gene therapy, cell therapy, and genome engineering.

Highlights
SGMO's debt is down by 6% YoY and by 3.2% QoQ
Sangamo Therapeutics's net income has shrunk by 139% YoY and by 34% QoQ
The EPS has dropped by 115% year-on-year and by 34% since the previous quarter

Key stats

What are the main financial stats of SGMO
Market
Shares outstanding
145.67M
Market cap
$1.17B
Enterprise value
$1.02B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.87
Price to sales (P/S)
10.73
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.44
Earnings
Revenue
$108.52M
EBIT
-$180.91M
EBITDA
-$164.47M
Free cash flow
-$209.26M
Per share
EPS
-$1.27
Free cash flow per share
-$1.44
Book value per share
$2.79
Revenue per share
$0.75
TBVPS
$4.66
Balance sheet
Total assets
$772.4M
Total liabilities
$366.38M
Debt
$36.12M
Equity
$406.02M
Working capital
$315.5M
Liquidity
Debt to equity
0.09
Current ratio
3.39
Quick ratio
3.28
Net debt/EBITDA
0.87
Margins
EBITDA margin
-151.6%
Gross margin
100%
Net margin
-167.2%
Operating margin
-172.2%
Efficiency
Return on assets
-21.2%
Return on equity
-39.9%
Return on invested capital
-35.6%
Return on capital employed
-28.2%
Return on sales
-166.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SGMO stock price

How has the Sangamo Therapeutics stock price performed over time
Intraday
-3.38%
1 week
-10.4%
1 month
-7.51%
1 year
-20.61%
YTD
-48.69%
QTD
-11.1%

Financial performance

How have Sangamo Therapeutics's revenue and profit performed over time
Revenue
$108.52M
Gross profit
$108.52M
Operating income
-$186.87M
Net income
-$181.39M
Gross margin
100%
Net margin
-167.2%
SGMO's operating margin has dropped by 199% year-on-year and by 67% since the previous quarter
Sangamo Therapeutics's net income has shrunk by 139% YoY and by 34% QoQ
The operating income has plunged by 121% YoY and by 31% from the previous quarter
SGMO's net margin has shrunk by 70% QoQ

Growth

What is Sangamo Therapeutics's growth rate over time

Valuation

What is Sangamo Therapeutics stock price valuation
P/E
N/A
P/B
2.87
P/S
10.73
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.44
The EPS has dropped by 115% year-on-year and by 34% since the previous quarter
The price to book (P/B) is 24% lower than the 5-year quarterly average of 3.8 and 24% lower than the last 4 quarters average of 3.8
The equity fell by 22% YoY and by 9% QoQ
The stock's P/S is 41% below its 5-year quarterly average of 18.2 and 23% below its last 4 quarters average of 14.0
The revenue is down by 26% year-on-year and by 21% since the previous quarter

Efficiency

How efficient is Sangamo Therapeutics business performance
The ROE has plunged by 145% YoY and by 43% from the previous quarter
The company's return on assets has shrunk by 116% YoY and by 41% QoQ
Sangamo Therapeutics's return on invested capital has shrunk by 90% YoY and by 42% QoQ
The return on sales has dropped by 70% since the previous quarter

Dividends

What is SGMO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SGMO.

Financial health

How did Sangamo Therapeutics financials performed over time
SGMO's total assets is 111% greater than its total liabilities
The quick ratio has declined by 41% year-on-year and by 17% since the previous quarter
The company's current ratio fell by 40% YoY and by 16% QoQ
SGMO's debt is 91% lower than its equity
Sangamo Therapeutics's debt to equity has increased by 29% YoY and by 13% QoQ
The equity fell by 22% YoY and by 9% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.